NCT07139951View on ClinicalTrials.gov

Hyperthermic Intraperitoneal Chemotherapy With Cisplatin and Paclitaxel for the Treatment of Patients With Gastric and Gastroesophageal Junction Adenocarcinoma at High Risk of Peritoneal Recurrence

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

September 11, 2025

Primary Completion Date

February 11, 2027

Study Completion Date

August 11, 2031

Conditions
Clinical Stage I Gastric Cancer AJCC v8Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage II Gastric Cancer AJCC v8Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage III Gastric Cancer AJCC v8Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8Gastric AdenocarcinomaGastroesophageal Junction Adenocarcinoma
Interventions
PROCEDURE

Biopsy Procedure

Undergo laparoscopy with biopsy

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

DRUG

Cisplatin

Given IP

PROCEDURE

Computed Tomography

Undergo PET/CT

DRUG

Hyperthermic Intraperitoneal Chemotherapy

Given p-HIPEC

PROCEDURE

Laparoscopy

Undergo laparoscopy with biopsy

PROCEDURE

Lymphadenectomy

Undergo D2 lymphadenectomy

PROCEDURE

Magnetic Resonance Imaging

Undergo PET/MRI

DRUG

Paclitaxel

Given IP

PROCEDURE

Positron Emission Tomography

Undergo PET/CT or PET/MRI

PROCEDURE

Surgical Procedure

Undergo gastrectomy and reconstruction

Trial Locations (1)

55905

Mayo Clinic in Rochester, Rochester

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
lead

Mayo Clinic

OTHER